This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients With Plaque Psoriasis With or Without Concomitant Psoriatic Arthritis
Sponsor: AbbVie
A PHASE1 clinical study on Psoriasis, this trial is completed. The trial is conducted by AbbVie and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .